Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Virpax Pharmaceuticals, Inc. (VRPX)
:VRPX
Holding VRPX?
Track your performance easily
VRPX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.29 - $5.48
Previous CloseN/A
Volume440.71K
Average Volume (3M)1.31M
Market Cap
$4.62M
Enterprise Value$3.22M
Total Cash (Recent Filing)$48.37K
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta0.21
Next Earnings
Mar 26, 2025EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.82
Shares Outstanding14,887,581
10 Day Avg. Volume456,069
30 Day Avg. Volume1,310,434
Standard Deviation0.59
R-Squared0.00563
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.10
P/FCF Ratio0.00
Enterprise Value/Market Cap0.70
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-0.39
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
Virpax Pharmaceuticals News
PremiumCompany Announcements
Virpax Updates Executive Agreements for Legal Compliance
PremiumCompany Announcements
Virpax Pharmaceuticals Welcomes Jay Panis to Board
PremiumCompany Announcements
Virpax Pharmaceuticals Announces Board Member Resignation
PremiumMarket News
3 Penny Stocks to Watch Now, 11/26/24
PremiumCompany Announcements
Virpax Pharmaceuticals Strengthens Leadership and Expands Collaborations
PremiumCompany Announcements
Virpax Pharmaceuticals Announces New Chief Financial OfficerBulls Say, Bears Say
Bulls Say
InnovationEnvelta is a novel analgesic with broad pain management potential.
Product DevelopmentVirpax has promising pre-clinical central nervous system (CNS) assets, primarily in pain management, with Probudur and Envelta.
Product PotentialProbudur could be a ~96 hour bupivacaine-based post-operative pain therapy.
Bears Say
Cash Flow And FundingCash on hand at quarter-end only provides sufficient funding through the end of 3Q24.
Financial StabilityVirpax did not consummate a ≥$5M financing with an institutional investor as previously agreed upon, increasing the risk that the financing cannot be completed.
Leadership StabilityVirpax's CEO and CFO both resigned, along with multiple board members, due to disagreements with execution of policies, practices, and procedures.
---
Ownership Overview
0.12%
Insiders
0.08% Mutual Funds
0.39% Other Institutional Investors
99.37% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
VRPX FAQ
What was Virpax Pharmaceuticals, Inc.’s price range in the past 12 months?
Virpax Pharmaceuticals, Inc. lowest stock price was $0.29 and its highest was $5.48 in the past 12 months.
What is Virpax Pharmaceuticals, Inc.’s market cap?
Virpax Pharmaceuticals, Inc.’s market cap is $4.62M.
When is Virpax Pharmaceuticals, Inc.’s upcoming earnings report date?
Virpax Pharmaceuticals, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 64 days.
How were Virpax Pharmaceuticals, Inc.’s earnings last quarter?
Virpax Pharmaceuticals, Inc. released its earnings results on Nov 12, 2024. The company reported -$0.54 earnings per share for the quarter, the consensus estimate of -$0.54 by $0.
Is Virpax Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Virpax Pharmaceuticals, Inc.’s price is currently Overvalued.
Does Virpax Pharmaceuticals, Inc. pay dividends?
Virpax Pharmaceuticals, Inc. does not currently pay dividends.
What is Virpax Pharmaceuticals, Inc.’s EPS estimate?
Virpax Pharmaceuticals, Inc.’s EPS estimate is -0.27.
How many shares outstanding does Virpax Pharmaceuticals, Inc. have?
Virpax Pharmaceuticals, Inc. has 14,887,581 shares outstanding.
What happened to Virpax Pharmaceuticals, Inc.’s price movement after its last earnings report?
Virpax Pharmaceuticals, Inc. reported an EPS of -$0.54 in its last earnings report, expectations of -$0.54. Following the earnings report the stock price went down -6.061%.
Which hedge fund is a major shareholder of Virpax Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in VRPX
---
Company Description
Virpax Pharmaceuticals, Inc.
Virpax Pharmaceuticals Inc is a preclinical-stage pharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management.
---
Technical Analysis
---